{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:41:41Z","timestamp":1780576901734,"version":"3.54.1"},"reference-count":24,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Pleural mesothelioma (PM) is an inflammatory cancer linked with asbestos exposure and has a poor prognosis. We report results of the phase 1b KEYNOTE\u2010A17 study (NCT04153565) of first\u2010line pembrolizumab plus chemotherapy in Japanese participants with advanced PM. Participants aged \u2265\u200920\u2009years with previously untreated, histologically confirmed advanced or unresectable PM received pembrolizumab 200\u2009mg every 3\u2009weeks (Q3W) for \u2264\u200935\u2009cycles with cisplatin 75\u2009mg\/m<jats:sup>2<\/jats:sup> and pemetrexed 500\u2009mg\/m<jats:sup>2<\/jats:sup> Q3W for 4\u20136\u2009cycles. Primary endpoints were the rate of dose\u2010limiting toxicities (DLTs), adverse events (AEs), and treatment discontinuations due to AEs. DLTs were assessed during cycle 1 in 18 participants, and having \u2264\u20098 participants with DLTs was considered tolerable. AEs were graded per NCI CTCAE 5.0. Tumor response was evaluated per modified RECIST for PM by the investigator. Among 19 participants enrolled, the median study follow\u2010up was 30.8 (range, 27.8\u201333.3) months (data cutoff September 21, 2022). Of 18 participants evaluated for DLTs, 2 (11%) experienced 4 DLTs (hypoalbuminemia, malaise, pyrexia in 1 participant; uveitis in 1 participant). 18\/19 participants (95%) experienced treatment\u2010related AEs; 14 (74%) had grade 3\u20134 events (no grade 5). Treatment\u2010related AEs led to discontinuation of any drug in 5 participants (26%). The objective response rate was 74% (partial response, <jats:italic>n<\/jats:italic>\u2009=\u200914), and the median (range) duration of response was 16.8 (3.0\u201326.3+) months. First\u2010line pembrolizumab plus chemotherapy was tolerable based on the low incidence of DLTs and showed acceptable safety and preliminary antitumor activity in Japanese participants with advanced PM.<\/jats:p><jats:p><jats:bold>Trial Registration:<\/jats:bold> NCT04153565<\/jats:p>","DOI":"10.1111\/cas.70082","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T09:20:03Z","timestamp":1747992003000},"page":"2208-2217","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["<scp>KEYNOTE<\/scp>\u2010<scp>A17<\/scp>: First\u2010Line Pembrolizumab Plus Cisplatin\u2013Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4249-4021","authenticated-orcid":false,"given":"Takashi","family":"Kijima","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine and Hematology Hyogo Medical University  Hyogo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-1424","authenticated-orcid":false,"given":"Terufumi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Kanagawa Cancer Centre  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7437-5054","authenticated-orcid":false,"given":"Yasushi","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology National Cancer Centre Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Kuribayashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Hematology Hyogo Medical University  Hyogo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Mikami","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Hematology Hyogo Medical University  Hyogo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Negi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Hematology Hyogo Medical University  Hyogo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5104-5493","authenticated-orcid":false,"given":"Shuji","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Kanagawa Cancer Centre  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4896-5824","authenticated-orcid":false,"given":"Tatsuya","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology National Cancer Centre Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masae","family":"Homma","sequence":"additional","affiliation":[{"name":"MSD K.K  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Wakana","sequence":"additional","affiliation":[{"name":"MSD K.K  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Noguchi","sequence":"additional","affiliation":[{"name":"MSD K.K  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4516-0433","authenticated-orcid":false,"given":"Nobukazu","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Okayama Rosai Hospital  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.11.23"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010238"},{"key":"e_1_2_11_4_1","first-page":"70","article-title":"Mesothelioma: A Review","volume":"12","author":"Mott F. E.","year":"2012","journal-title":"Ochsner Journal"},{"key":"e_1_2_11_5_1","article-title":"Life Expectancy in Pleural and Peritoneal Mesothelioma","volume":"2017","author":"Shavelle R.","year":"2017","journal-title":"Lung Cancer (International Edition)"},{"key":"e_1_2_11_6_1","first-page":"491","article-title":"Malignant Pleural Mesothelioma: An Epidemiological Perspective","volume":"1","author":"Robinson B. M.","year":"2012","journal-title":"Annals of Cardiothoracic Surgery"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.e12007"},{"key":"e_1_2_11_8_1","unstructured":"National Comprehensive Cancer Network (NCCN) \u201cNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Malignant Pleural Mesothelioma. Version 1.2020 \u201d2019 https:\/\/www.nccn.org."},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.074"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30169-9"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30515-4"},{"key":"e_1_2_11_13_1","volume-title":"KEYNOTE\u2010189: Randomized, Double\u2010Blind, Phase 3 Study of Pembrolizumab (Pembro) or Placebo Plus Pemetrexed (Pem) and Platinum as First\u2010Line Therapy for Metastatic NSCLC","author":"Gandhi L.","year":"2018"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01613-6"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-017-4424-6"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh059"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774507079442"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14980"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyn024"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.2035"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.02.003"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100135"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01541-0"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003288"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.70082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T08:34:18Z","timestamp":1754296458000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.70082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/cas.70082"],"URL":"https:\/\/doi.org\/10.1111\/cas.70082","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"2024-08-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}